How have IGC shares performed in 2023?

IGC Pharma's stock was trading at $0.40 at the beginning of 2023. Since then, IGC stock has decreased by 24.3% and is now trading at $0.3027. View the best growth stocks for 2023 here .

Are investors shorting IGC Pharma?

IGC Pharma saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 970,000 shares, an increase of 16.2% from the October 15th total of 835,000 shares. Based on an average daily volume of 248,200 shares, the days-to-cover ratio is currently 3.9 days. View IGC Pharma's Short Interest .

How were IGC Pharma's earnings last quarter?

IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its quarterly earnings data on Thursday, November, 9th. The construction company reported ($0.05) earnings per share for the quarter. The construction company earned $0.29 million during the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 71.40% and a negative net margin of 803.94%.

What other stocks do shareholders of IGC Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH) , Alibaba Group (BABA) , Tilray (TLRY) , Cronos Group (CRON) , Micron Technology (MU) , NewAge (NBEV) , Advanced Micro Devices (AMD) , Ford Motor (F) and NIO (NIO) .

Who are IGC Pharma's major shareholders?

IGC Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Commonwealth Equity Services LLC (0.31%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ram Mukunda and Richard K Prins. View institutional ownership trends .

How do I buy shares of IGC Pharma?

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

IGC Pharma Stock Price, News & Analysis (NYSEAMERICAN:IGC)

$0.30

0.00 (0.00%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.30
▼
$0.31
50-Day Range: N/A
52-Week Range: $0.27
▼
$0.49

Volume: 76,622 shs
Average Volume: 173,770 shs
Market Capitalization: $19.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines Ownership SEC Filings Short Interest

About IGC Pharma Stock (NYSEAMERICAN:IGC)

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IGC Stock News Headlines

December 6, 2023 | finance.yahoo.com

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

December 6, 2023 | americanbankingnews.com

IGC Pharma (NYSEAMERICAN:IGC) Share Price Crosses Above 200 Day Moving Average of $0.00

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

November 24, 2023 | money.usnews.com

IGC Pharma Inc

November 22, 2023 | msn.com

AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research

November 21, 2023 | finance.yahoo.com

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

November 13, 2023 | finance.yahoo.com

IGC Pharma Reports Second Quarter Fiscal 2024 Results

October 19, 2023 | finance.yahoo.com

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

December 8, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

September 8, 2023 | finance.yahoo.com

IGC Pharma, Inc. (IGC)

August 21, 2023 | finance.yahoo.com

IGC Announces Results of its 2023 Annual Stockholders Meeting

August 14, 2023 | finance.yahoo.com

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials

August 9, 2023 | msn.com

IGC powers Alzheimer’s and cannabis research with AI

August 3, 2023 | benzinga.com

THC-Based Alzheimer's Trial In Puerto Rico: IGC Pharma Targets Underrepresented Hispanic Communities

August 2, 2023 | finance.yahoo.com

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

July 18, 2023 | finance.yahoo.com

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference

July 12, 2023 | msn.com

IGC Pharma FY23 Revenue Grows 129%, What About Net Loss?

July 12, 2023 | finance.yahoo.com

IGC Reports Financial Results for Fiscal Year Ended March 31, 2023

July 7, 2023 | benzinga.com

IGC Pharma Secures $12M Credit Facility From O-Bank To Aid Alzheimer's Research

July 6, 2023 | msn.com

IGC Pharma Secures $3M Via Private Placement

July 6, 2023 | msn.com

IGC Raises $3M Via Private Placement With Asset Management Firm Bradbury

July 6, 2023 | finance.yahoo.com

IGC Pharma Announces a $3 Million Private Placement of its Common Stock

June 16, 2023 | fool.com

India Globalization Capital (NYSEMKT: IGC)

June 6, 2023 | finance.yahoo.com

IGC Pharma Receives Notice of Allowance for Patent on Seizures

June 5, 2023 | finance.yahoo.com

IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award

May 18, 2023 | finance.yahoo.com

IGC Pharma to Present at LD Micro Invitational XIII

May 8, 2023 | marketwatch.com

8-K: IGC Pharma, Inc.

See More Headlines

Receive IGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/08/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:IGC
CUSIP: N/A
CIK: 1326205
Web: www.igcinc.us
Phone: (301) 983-0998
Fax: 240-465-0273
Employees: 61
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,510,000.00
Net Margins: -803.94%
Pretax Margin: -803.94%
Return on Equity: -71.40%
Return on Assets: -62.25%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 2.90
Quick Ratio: 1.65

Sales & Book Value

Annual Sales: $910,000.00
Price / Sales: 21.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.28 per share
Price / Book: 1.07

Miscellaneous

Outstanding Shares: 63,730,000
Free Float: 51,625,000
Market Cap: $19.12 million
Optionable: Not Optionable
Beta: 1.69

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Ram Mukunda (Age 64)
President, CEO & Director
Comp: $705k
Ms. Claudia Grimaldi (Age 52)
VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director
Comp: $245k
Mr. Rohit Goel (Age 29)
Senior Director of Accounting & Principal Accounting Officer

Key Competitors

View All Competitors

Institutional Ownership

Commonwealth Equity Services LLC
Bought 112,334 shares on 10/23/2023
Ownership: 0.308%

View All Institutional Transactions

IGC Stock Analysis - Frequently Asked Questions

How have IGC shares performed in 2023?: IGC Pharma's stock was trading at $0.40 at the beginning of 2023. Since then, IGC stock has decreased by 24.3% and is now trading at $0.3027.
View the best growth stocks for 2023 here.
Are investors shorting IGC Pharma?: IGC Pharma saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 970,000 shares, an increase of 16.2% from the October 15th total of 835,000 shares. Based on an average daily volume of 248,200 shares, the days-to-cover ratio is currently 3.9 days.
View IGC Pharma's Short Interest.
How were IGC Pharma's earnings last quarter?: IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its quarterly earnings data on Thursday, November, 9th. The construction company reported ($0.05) earnings per share for the quarter. The construction company earned $0.29 million during the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 71.40% and a negative net margin of 803.94%.
What other stocks do shareholders of IGC Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO).

Who are IGC Pharma's major shareholders?: IGC Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Commonwealth Equity Services LLC (0.31%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ram Mukunda and Richard K Prins.
View institutional ownership trends.
How do I buy shares of IGC Pharma?: Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:IGC) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial